Opinion

Video

Remaining unmet needs in diverse populations with mHSPC

Enhancing minority enrollment in clinical trials and utilizing real-world data improves drug safety and efficacy for mHSPC treatments.

Future Research Directions

Key Themes:

  • There is a need for continued efforts to improve minority enrollment in clinical trials.
  • The importance of real-world evidence to complement trial data is growing.
  • A combined approach should use trial and real-world data for comprehensive assessment.
  • Future research should prioritize diversity and representation.

Key Points for Physicians:

  • Stay informed about evolving evidence from clinical trials and real-world data.
  • Support efforts to improve diversity in research.
  • Consider contributing to real-world evidence generation.
  • Recognize limitations in current evidence while awaiting more comprehensive data.

Notable Insights: Real-world evidence provides an important complement to clinical trial data, particularly for understanding outcomes in traditionally underrepresented populations.

Clinical Significance: Ongoing commitment to inclusive research and evidence generation will improve the quality and equity of prostate cancer care, particularly for populations historically underrepresented in clinical trials.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.